Deliver“medicines that matter”for patients Deliver“medicines that matter”for patients

news news


ARTham Therapeutics Presents Preclinical Data from Its Clinical NASH Candidate ART-648 at The International Liver Congress

YOKOHAMA, February 12, 2019 – ARTham Therapeutics, Inc., a clinical st

mission mission

Deliver “medicines that matter” to improve patient health and contribute to enhanced quality of life. At ARTham Therapeutics, we will create value by developing innovative medicines that are disease modifying and improve patient health.

Value Value

ARTham Therapeutics Inc., is a clinical stage biopharmaceutical company that will deliver ‘medicines that matter’ for patients. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To deliver on cost and time efficiency, ARTham will run a virtual R&D operating model that seeks innovation through the best academic and business partners.

team team

  • Sham Nikam,

    read more read more

    Former VP, Head of Innovation & Entrepreneurship,Extra Value Generation Drug
    Discovery Unit, Takeda Pharmaceuticals;
    Global Head of Discovery, Nycomed, Zurich;
    Director, Chemistry & Neuroscience
    Therapeutic Area, Parke-Davis/Warner Lambert and Pfizer; Smith Kline & French Labs (now GSK), Sandoz (now Novartis); Adjunct Associate Professor, University of Michigan, Ann Arbor
    Expert in drug discovery/early development
    medicinal chemistry, CMC, informatics, drug repositioning

  • Hiroshi Nagabukuro,

    read more read more

    Visiting lecturer, Oita University
    Visiting fellow, Yokohama City University
    Former Sr Director, Innovation & Entrepreneurship, Extra Value Generation Drug Discovery Unit,
    Takeda Pharmaceuticals.; Research Fellow, Merck Research Labs, USA; Visiting Fellow, Florida State University
    Expert in pharmacology, translational medicine, drug repositioning

  • Naoto Uemura,
    M.D., Ph.D.

    Chief Medical Advisor
    read more read more

    Professor, Clinical Pharmacology, Oita University;
    Adjunct Professor, Osaka University
    Former Director and International Fellow, Clinical Research, Merck Research Labs, USA;
    Visiting Research Scholar University of California at San Francisco (UCSF)
    Expert in clinical pharmacology, translational medicine,
    early clinical development

  • Akira Tanaka

    Senior Director
    Clinical Science
    read more read more

    Visiting scholar, Oita University
    Former Clinical Scientist, Takeda Gastrointestinal Therapeutic Area Unit, Boston, USA; Principal Scientist, Extra Value Generation Drug Discovery Unit, Oncology Drug Discovery Unit, Takeda Pharmaceuticals
    Expert in clinical science, pharmacology, endocrinology, oncology, drug repositioning

  • Kanako Kuniyeda, Ph.D.

    Associate Director
    Discovery Science
    read more read more

    Former Principal Scientist, Innovative Biology Labs, Extra Value Generation Drug Discovery Unit, Takeda Pharmaceuticals
    Expert in biochemistry, molecular biology, drug repositioning

  • Sham Nikam,

  • Hiroshi Nagabukuro,

  • Hiroyuki Misawa,

    Partner at Miyako Capital
  • Jonathan Lanfear

    Global Head, R&D Business
    at Takeda Pharmaceuticals

Our passion is to unravel hidden value of preclinical and clinical assets via cutting edge science . This will be driven by deeper understanding of disease etiology, relevance to target mechanisms and optimal modality to deliver drugs that ultimately help patients to be healthy.

ART-648 ART-648

New treatment for NASH

ART-648: First PDE4 inhibitor candidate for effective treatment of NASH.
・Key pathological features of NASH are steatosis, inflammation and fibrosis
・Anti-inflammatory effect of PDE4 inhibition has been proven in clinic
・Significant treatment effects on steatosis, inflammation and fibrosis were observed in murine NASH models
・Ph1 clinical trial is currently being conducted in Japan

NASH is a progressive form of NAFLD (Non Alcoholic Fatty Liver Disease) with patients that advance to fibrosis due to inflammatory processes that result into cirrhosis or liver cancer. There is no approved pharmacotherapy for NASH.
Although it is difficult to obtain an accurate estimate of NASH prevalence given the fact that NASH is a silent disease, there is a report that the global prevalence of NAFLD is as high as one billion. In the United States, NAFLD is estimated to be the most common cause of chronic liver disease, affecting between 80 and 100 million individuals, among whom nearly 25% progress to NASH (World J Gastroenterol 2017, 23: 8263-8276) .
Analysts predict NASH drug market could reach anywhere between $25-$35 billion by 2025 (Reuters BUSINESS NEWS, APRIL 24, 2017; BusinessWire February 12, 2018)

ART-001 ART-001

New Effective Treatment for Vascular Malformations

ART-001: First in Class PI3K (phosphatidylinositol-3-kinase) inhibitor for the treatment of vascular malformations and overgrowth syndromes
・Significant unmet medical need with no current pharmacotherapy
・Patient with GOF mutation of PI3K-AKT pathway
・Selective inhibition of angiogenesis
・This program has received a grant from AMED, Japanese Agency for Medical Research and Development.

Vascular malformations are benign (non-cancerous) lesions that are present at birth, but may become visible for weeks or months after birth. Unlike hemangiomas, vascular malformations do not have a growth cycle and then regress but instead continue to grow slowly throughout life. Most vascular malformations are sporadic (occurring by chance), though some are inherited in a family as an autosomal dominant trait.

Contact us Contact us